How are we doing?

Information on how the performance of individual clinicians, teams and hospitals compares with the best is key to driving up standards in cancer care. ECCO is designing and implementing an audit framework named EURECCA to [more]

Newsround

Everolimus plus octreotide improves progression-free survival in advanced NET => The Lancet The addition of everolimus to octreotide improved progression-free survival in patients with advanced neuroendocrine tumours (NETs) associated with carcinoid syndrome, the phase III [more]

UA-77507851-1